Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of erdafitinib in treating patients with prostate
cancer that grows and continues to spread despite the surgical removal of the testes or drugs
to block androgen production (castration-resistant). Erdafitinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Giving erdafitinib may help
control disease in patients with castration-resistant prostate cancer. In addition, studying
samples of blood, tissue, plasma, and bone marrow from patients with castration-resistant
prostate cancer in the laboratory may help doctors learn more about changes that occur in
deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.